SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

NARHEX LIFE SCIENCES LIMITED (NLS)

Former Name ASX

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

Shareholder links

Our website ranking of NLS: rating 3
(3 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Link Market Services, Level 12 QV1 Building 250 St Georges Terrace Perth WA 6000

Tel : +61 8 9211 6670 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

Address: Level 24, 44 St Georges Terrace, PERTH, WA, AUSTRALIA, 6000
Tel:  (08) 6211 5099 Fax: (08) 9218 8875

Date first listed: 12/01/2005
Company Secretary: Ms Nicki Farley
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Australian biotechnology company with a principal focus to develop and commercialize its anti-HIV protease inhibitor DG17

name changed to ResApp Health Limited

08/07/2015

The Company is pleased to announce that the Share Sale Agreement dated 20 February 2015 between the Company, ResApp Diagnostics Pty Ltd ("ResApp"), the Shareholders of ResApp and UniQuest Pty Ltd has completed with the Company acquiring 100% of ResApp.

02/07/2015

Narhex Life Sciences Limited ("Company") is pleased to announce that its Capital Raising has closed oversubscribed, with funds totalling $4,000,000 having been raised under the Company's Replacement Prospectus dated 26 May 2015. The Company will now proceed to complete its acquisition of ResApp Diagnostics Pty Ltd and seek reinstatement of its securities on the ASX.

12/06/2015

The company provides a new issue announcement, an application for quotation of additional securities and agreement.

04/06/2015

As approved by Shareholders of Narhex Life Sciences Limited at the General Meeting held on 27 May 2015, the Capital Consolidation on a 3:8 basis has been completed, with the resulting capital structure detailed in the announcement.

04/06/2015

Narhex Life Sciences Limited (ASX: NLS) is pleased to advise in accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act, details of the resolutions and proxies received for the General Meeting held on 27 May 2015. All resolutions were passed on a show of hands including Resolutions 3 and 11 which were passed as special resolutions.

27/05/2015

The securities of Narhex Life Sciences Limited (the "Company") will be suspended from official quotation immediately, pending the outcome of a resolution at the Company's general meeting to approve a change in the Company's activities. The Company's securities will remain suspended pending compliance with Chapters 1 and 2 of the Listing Rules. Security Code: NLS

27/05/2015

the suspension of trading in the securities of Narhex Life Sciences Limited will be lifted before the commencement of trading today, Monday 14 March 2011

14/03/2011

board confirms that it is in compliance with the Listing Rules

10/03/2011

company lodges various financial reports including Half Year Accounts to 31 December 2010 - they feature a great deal of red ink

09/03/2011

the Company's Deed of Company Arrangement has been wholly effectuated with control of the Company having reverted back to the Directors

18/01/2011

we understand that on or about this date the company consolidated its shares 1 for 10

15/11/2010

at the GM of the shareholders of Narhex Life Sciences Limited held today in Melbourne, shareholders considered the items of business as set out in the Notice of Meeting dated 5 October 2010 and passed each of resolutions 1 - 7 by a show of hands

05/11/2010

a General Meeting to be held at Level 2, 90 William Street, Melbourne, Victoria, 3000 on 5 November 2010 commencing at 10AM (EST) - this is to consider the proposed recapitalisation of the Company including the consolidation of the Existing Shares in the Company on a 1 for 10 basis

07/10/2010

a Deed of Company Arrangement is executed

07/05/2010

David Ross and Richard Albarran of Hall Chadwick are appointed as administrators of the company - this does not augur well for shareholders

09/02/2010

releases quarterly report

01/02/2010

the Board of Directors advises that Dr Michael Cohen, the Company's Executive Chairman and Acting Managing Director, passed away suddenly overnight

19/11/2009

at the AGM of the shareholders of NLS held today in Melbourne, shareholders passed each of Resolutions no. 1 - 7 as set out in the Notice of Meeting dated 4 September 2009

16/10/2009

the AGM is to be held at 11:00am Friday 16 October 2009 at the offices of Lander & Rogers, Level 12, 600 Bourke Street, Melbourne Vic 3000

17/09/2009

releases Half Yearly Report and Accounts to December 2007 and Financial and Annual Report June 2008

16/07/2009

company responds to an ASX Query re Appendix 4C

21/11/2008

releases Quarterly report for entities admitted on the basis of commitments

31/10/2008

main items in the quarterly cash flow to June 2008 are R&D expense of $103k, an R&D refund of $193k and $114k cash remaining

31/07/2008

the company explains the reasons for its suspension from quotation and provides an update for shareholders

21/07/2008

releases its quarterly cash report to 31 March 2008 showing a deficit at operating level for the quarter of $214k and $12k balance remaining

30/04/2008

securities suspended from quotation following failure to lodge its half report for the period ended 31 December 2007

03/03/2008

suspension of trading is lifted following receipt of the Company's Full Year Accounts for the period ended 30 June 2007

11/10/2007

securities suspended from quotation following failure to lodge financial statements for the period to 30 June 2007

01/10/2007

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    11/06/2014Cyril D'Silva949,000$0.003$2,847
    28/02/2014Cyril D'Silva151,000$0.006$906

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Adam SierakowskiChairman, Non Exec Director16/05/2013
    Chris NtoumenopoulosNon Exec Director22/01/2015
    Robert RamsayNon Exec Director20/12/2013

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Cyril D'SilvaExecutive Chairman16/05/201322/01/2015
    Peter ChristieChairman13/01/201120/12/2013
    David MandelDirector17/05/201020/12/2013
    Simon LillDirector13/01/201120/12/2013
    Ian ReynoldsDirector22/02/201330/04/2013
    Peter NashDirector07/10/200422/06/2012

    Date of first appointment, title may have changed.